Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia

(2015) Joris Berwaerts et al.   JAMA Psychiatry

A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia

(2014) Adriaan Cleton et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia

(2013) Nagahide Takahashi et al.   Neuropsychiatric Disease and Treatment

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

(2012) Danielle Coppola et al.   BMC Psychiatry

Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia

(2012) Rebecca Schennach et al.   PSYCHIATRIC SERVICES

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia

(2011) W. Wolfgang Fleischhacker et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

(2011) Huafang Li et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

(2010) Srihari Gopal et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia

(2010) Gahan J. Pandina et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

(2010) S Gopal et al.   JOURNAL OF PSYCHOPHARMACOLOGY

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

(2010) Henry A Nasrallah et al.   NEUROPSYCHOPHARMACOLOGY

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

(2010) Gahan Pandina et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia

(2009) Mahesh N. Samtani et al.   CLINICAL PHARMACOKINETICS

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

(2009) Michelle Kramer et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia

(2009) David Hough et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

(2009) David Hough et al.   SCHIZOPHRENIA RESEARCH